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or sibutramine (10mg/d) in a randomized, controlled, single-
blind clinical study, and evaluated weight and satisfaction during
six-weeks of this treatment. RESULTS: A total of 40 females 36
+/- 4yr with orlistat; and 40 females, aged 37 +/- 6yr with sibu-
tramine) completed six-weeks on exercise and a controlled-
energy diet. Orlistat was well tolerated, with gastrointestinal
adverse effects as well as inhibiting the assimilation of fat from
the bowel. It was approved for long-term treatment of obesity
while sibutramine acted on the cns to control appetite or enhance
the feeling of saturation. Signiﬁcant body mass index (bmi)
improvement was detected after six-weeks (p < 0.05) in both
groups (p = 0.02, p = 0.04 respectively). Signiﬁcant waist cir-
cumference (wc), but not signiﬁcant hip circumference (hc),
improvement were observed in both groups (p = 0.03, p = 0.14,
p = 0.04, p = 0.21 respectively). Orlistat and sibutramine were
not signiﬁcantly different in terms of weight reduction effect (p
= 0.14). However, patients were more satisﬁed with oristat than
sibutramine (p = 0.02). CONCLUSIONS: Orlistat and sibu-
tramine could signiﬁcantly reduce weight. However, patients
were more satisﬁed with orlistat than sibutramine.
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OBJECTIVE: Patterns of obesity are an important public health
consideration. The purpose of this study was to determine the
past and future population trends of obesity in the UK (UK).
METHODS: Data describing body mass index (BMI) were
abstracted from the English Health Survey’s from 1991 to 2002,
inclusive. The UK was assumed to follow the same pattern of
change in body composition as England. The distributional
pattern of BMI was determined and age and sex speciﬁc changes
in the distribution described over the period. Data were stan-
dardized to the UK population in 2001. Ethnicity was accounted
for in the forecast using general linear models for age and sex
speciﬁc groups applied to government forecasts of future demog-
raphy. RESULTS: BMI increased by a mean value of 1.21kg/m2
(standard error of the mean (SEM) 0.105 to 0.044 [≥18 years]),
equivalent to an annual increase of 0.11kg/m2 per year (95% CI
0.106 to 0.123). BMI in women increased on average from 25.6
to 26.8kg/m2, and men’s from 25.9 to 27.1kg/m2. This varied
by age and sex. The annual change in mean BMI was linear in
every age group. In 1991 and 2002 the proportion of overweight
(≥25.0 to <30.0kg/m2) and obese (≥30.0kg/m2) people in the
population rose from 29.5% and 12.0%, to 31.3% and 18.4%,
respectively. The number of overweight and obese people in the
general population in 2004 was estimated to be 31.2 million
people (52.6%), increasing to 38.0 million people (62.0%) in ten
years time, an increase of 6.8 million people. CONCLUSION: If
reliable, this estimate clearly represents a serious public health
challenge.
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OBJECTIVES: To assess epidemiologic trends of overweight and
obesity and to examine treatment patterns to control weight in
children/adolescents aged 2–19 years and for adults ≥20 years
old. METHODS: The Third National Health and Nutrition
Examination Survey (NHANES III) conducted in 1988–1994
and NHANES 2001–2002 were used. Children/adolescents 
were classiﬁed as at risk for overweight if body mass index (BMI)
was ≥85th–<95th percentile and as overweight if BMI was at
≥95th percentile of the sex-speciﬁc BMI for age growth charts.
Adults were categorized as overweight (BMI 25.0–29.9) or obese
(BMI ≥ 30.0). Duration of physical activity was calculated 
using leisure-time physical activity to assess compliance of
CDC/ASCM recommendations. SAS and SUDAAN software
were employed to account for the complex survey design.
RESULTS: The proportions of children/adolescents at risk for
overweight or overweight increased from 13.1% to 14.5% 
and from 11.1% to 15.5%, respectively, between 1988–1994
and 2001–2002. The prevalence of overweight and obesity for
adults also increased from 32.8% to 35.2% and from 22.3% to
30.2%. Prevalence of diabetes in overweight and obese adults
slightly increased between 1988–1994 (5.5%, 10.0% respec-
tively) and 2001–2002 (6.1%, 10.6%). However, LDL ≥ 130
mg/dL was less prevalent in 2001–2002 (53.4% to 41.8% 
for overweight and 54.0% to 41.0% for obesity). Overall,
10.3% of overweight and 14.9% of obese adults used liquid diet
formula, prescription drugs, non-prescription drugs, laxatives or
vomiting to control weight in 2001–2002. Only 1% of over-
weight and 3% of obese adults took prescribed diet pills. About
47% of overweight and 43% of obese adults either took med-
ications or complied with physical activity recommended by
CDC/ASCM to control weight. CONCLUSIONS: Overweight
and obesity have become more prevalent in the US population
during the past decade. However, very few patients took med-
ications prescribed by their physicians to lose or control their
weight.
POB4
RELIABLE MEASUREMENT OF OBESITY: RISK OF VASCULAR
DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS
INDEX AND WAIST-TO- HIP RATIO
Woehl A1, Currie CJ2, McEwan P2, Peters JR3
1Kiel University, Kiel, Germany; 2Cardiff University, Cardiff, UK;
3University Hospital of Wales, Cardiff, UK
BMI is widely used to measure obesity in outcome studies, but
other easily collected measures are available to characterise
bodily shape. OBJECTIVE: The objective of this study was to
determine whether BMI and waist-to-hip ratio (W:H-R), as stan-
dard measures of obesity, collectively better explained the likeli-
hood of obesity-related complications. METHODS: This
retrospective study used data from the England Health Survey, a
national representative survey of the general population. Data
describing BMI, obesity related diseases and other anthropo-
metric measurements were abstracted from the survey 1991 to
1994, and 1997 to 2002. Using this data, a model was devel-
oped to account for various factors that could effect the devel-
opment of obesity related diseases: diabetes, stroke, heart attack,
hypertension and other vascular diseases. Using logistic regres-
sion, the association of between BMI categories further broken
down by W:H-R categories was determined. The results were
standardized for age, sex and ethnicity to generate standardized
odds ratios comparing the accuracy of different anthropometric
measurements and its combinations to predict obesity related
diseases. RESULTS: BMI and W:H-R were independent predic-
tors of disease in obesity. Using both these measures a more
precise prediction of the likelihood of developing obesity related
complications. Odds ratios in the group with the highest BMI of
the sample varied between 1.6 and 2.8 conditional on their W:
H-R. Patients with a medium BMI but high W:H-R had a higher
relative risk (odds ratio 1.8) than patients with a high BMI but
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low W:H-R (odds ratio 1.6). These patterns were even more
obvious in diabetic patients. Similar results could be shown by
combining BMI and waist circumference only. CONCLUSIONS:
BMI in addition to W:H-R or waist circumference is a better
and more precise predictor of obesity-related complications, and
should where possible be preferentially used. Longitudinal
obesity-related outcome data are needed.
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OBJECTIVE: To examine the cost-effectiveness of sibutramine
plus a structured weight management program (WMP) versus
only structured WMP. METHODS: Cost-effectiveness analysis
based on a randomized controlled trial conducted within a
managed care organization. The target population was obese or
overweight persons. The economic time horizon was two years
(pre and post study enrollment). Perspective was from that of a
managed care organization. The treatment arms consisted of
either sibutramine plus structured WMP or only WMP. The
primary outcomes were change in weight and percent change in
weight over 12 months, and change in obesity-related and total
medical costs 12 months prior to and 12 months after enroll-
ment. Non-parametric bootstrap was used to generate 95% con-
ﬁdence intervals for incremental cost-effectiveness ratios.
RESULTS: A total of 501 subjects were enrolled in the study,
281 receiving sibutramine plus structured WMP and 220 receiv-
ing only structured WMP. The mean (SD) weight loss was sig-
niﬁcantly greater in the sibutramine (13.7 (15.5) lbs) group than
the non-drug group (5.0 (13.2) lbs) (p < 0.001). Obesity-related
total cost between groups were different (p < 0.001), with a
median of $408 for sibutramine compared to $58 for the non-
drug group. The ICER for sibutramine was $44 (95% CI: $42
to $46) per additional pound of weight loss. Sensitivity analysis
suggested that changes in physician costs a negligible effect on
the results. If the cost of sibutramine was excluded, there was no
difference between the groups with respect to obesity-related
costs. A limitation of this study is that costs were estimated using
national fees schedules for hospital and physician visits and
average wholesale price for medications. CONCLUSION:
Patients enrolled in a weight management program receiving
sibutramine had greater weight loss and decrease in BMI at
greater cost than did patients enrolled in the same program who
did not receive sibutramine.
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OBJECTIVE: To provide a broad picture of the costs of obesity
using data from the US and major European countries.
METHOD: Literature (2000–2004) was searched via Medline
using cost keywords: cost, cost-effectiveness, cost-beneﬁt, cost-
efﬁciency. Selected citations were reviewed by title and abstract,
followed by retrieval of relevant articles, review and synthesis of
cost information. RESULT: Direct medical expenditures for
obesity in the US were estimated to be between $70–$94 billion
and $331 billion—with all obesity associated comorbidities
included. This represented approximately 5.7%–9.4% of the
adult direct health spending. Cardiovascular disease and diabetes
constituted approximately 70% of the obesity-related cost. Indi-
rect costs associated with obesity were estimated to be at least
$48 billion. The expected mean costs for persons with BMI =
30–34 and BMI = 35–39 were 12% and 19% higher (respec-
tively) than persons with BMI < 25. Women spent more than
men for obesity care. In the US, Wyoming showed the lowest
expenditure for obesity ($87 million), and California the highest
($7.7 billion). Direct costs of obesity in Europe were estimated
between 1.5% and 4% of total health expenditures, with the UK,
Germany and France all showing similar expenditures (1.5%).
Expenses associated with comorbid hypertension, coronary heart
disease and diabetes were the main drivers of cost in the UK
(80.5%). Indirect costs in the UK were estimated at £2.1 billion,
of which £1.3 billion (61%) was due to work loss. Drug inter-
ventions using Orlistat, Sibutramine and Metformin were all
cost-effective with the cost per QALY gained ranging between
$8,327 to $19,968 (£4,780 to £45,881). CONCLUSION: The
costs attributable to obesity in both the US and Europe repre-
sented a signiﬁcant portion of the national health expenditure
for those countries reviewed, with comorbid cardiovascular
disease and diabetes constituting the major components of
obsesity associated health care costs.
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OBJECTIVES: To Estimate the health care costs and clinical out-
comes of various body mass index (BMI) levels over a lifetime.
METHODS: A Markov model was developed to perform cost-
effectiveness/utility analyses to evaluate obesity treatments
including lifestyle, pharmacological and surgical interventions.
User-deﬁned cohorts of obese adults can be followed over a life-
time assessing changes in costs and life expectancy. Baseline 
risk factors include age, gender, race and BMI. First and second
order Monte Carlo simulation techniques were utilized. To
compare the outcomes of three distinct BMI groups a 20 year-
old Caucasian male with varying baseline BMI (25, 35 and 45
kg.m-2) was chosen and it was assumed that no medical inter-
vention was undertaken. The perspective was third-party reim-
bursement in a US setting. Mortality was adjusted for age,
gender, race and BMI by Cox regression and applied to US life
tables. Costs and utility values were adjusted for age, gender and
BMI. US costs were derived from published resources and
inﬂated to year 2004 ﬁgures. Reported outcomes included direct
medical costs, life expectancy (LE) and quality-adjusted life
expectancy (QALE) all of which were discounted at 3% accord-
ing to US guidelines. RESULTS: Mean lifetime costs were
$85,393 (±1545), $97,156 (±1836) and $97,542 (±2937) for
BMI levels of 25, 35 and 45kg.m-2 respectively. Undiscounted
LEs were 54.43(±1.47), 51.48 (±1.37) and 42.04 (±1.69) years
respectively. Lifetime costs associated with a BMI of 45kg.m-2
from age 20 were approximately 14% higher than costs associ-
ated with BMI 25kg.m-2. Undiscounted life expectancy was
reduced by 12.39 years and discounted QALE was reduced by
3.52 years for BMI 45kg.m-2 versus 25kg.m-2. CONCLU-
SIONS: Raised BMI is associated with substantially greater
direct medical costs and diminished LE and QALE. This model
will allow health economic evaluations of the outcomes of
various anti-obesity interventions.
